| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/26/2011 | WO2011061622A1 Compositions for treating centrally mediated nausea and vomiting |
| 05/26/2011 | WO2011061527A1 Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| 05/26/2011 | WO2011061332A1 Pharmaceutical composition comprising propofol |
| 05/26/2011 | WO2011061252A2 Combination therapy for treating or preventing an inflammatory skin disorder |
| 05/26/2011 | WO2011060943A1 Pharmaceutical formulations containing beta- blocking active ingredient capsules and polyunsaturated fatty acid esters |
| 05/26/2011 | WO2011038924A3 Proteasome inhibitors for treating cancer |
| 05/26/2011 | WO2010136872A3 Use of a glycosaminoglycan fixed combination and chewable composition comprising said fixed combination |
| 05/26/2011 | US20110124744 Magnetic Resonance-Based Viscometers and Methods |
| 05/26/2011 | US20110124739 Use of Sphingosine-1-phosphate (S1P) Receptor Agonists for the Treatment of Brain Degenerative Diseases |
| 05/26/2011 | US20110124697 Compositions based on aminoacids, suitable for the treatment of heart failure |
| 05/26/2011 | US20110124600 Use of Dopamine partial agonists for treament of the restless leg syndrome and corresponding pharmaceutical preparation |
| 05/26/2011 | US20110124580 Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto |
| 05/26/2011 | US20110123531 Combination therapy |
| 05/26/2011 | US20110123513 Alkaline phosphatase to reduce or prevent weight gain |
| 05/26/2011 | US20110123494 Treatment with anti-vegf antibodies |
| 05/26/2011 | US20110123488 Method of Treatment for Cancers Associated with Elevated HER2 Levels |
| 05/26/2011 | US20110123437 Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor |
| 05/26/2011 | DE102009046697A1 Agent, useful for treating stings, preferably jellyfish stings, and insect bites, comprises an aqueous soap solution, an antihistamine and a foaming agent |
| 05/26/2011 | CA2785376A1 Pharmaceutical composition |
| 05/26/2011 | CA2780586A1 Combination therapy for treating or preventing an inflammatory skin disorder |
| 05/26/2011 | CA2778301A1 Compositions for treating centrally mediated nausea and vomiting |
| 05/26/2011 | CA2776855A1 Pharmaceutical composition comprising propofol |
| 05/25/2011 | EP2325203A2 Cadherin materials and methods |
| 05/25/2011 | EP2324863A1 Method for producing artificial skin |
| 05/25/2011 | EP2324855A1 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 05/25/2011 | EP2324853A1 Lixisenatide as add-on to metformin in the treatment of diabetes type 2 |
| 05/25/2011 | EP2324852A1 Therapeutic or prophylactic agent for generalized pain syndrome |
| 05/25/2011 | EP2324843A1 Use of TNF-alpha inhibitors for treating nerve root injury |
| 05/25/2011 | EP2324839A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 05/25/2011 | EP2324834A2 Methods of Increasing Endogenous Erythropoietin (EPO) |
| 05/25/2011 | EP2324830A1 Process for the preparation of a monocyclic azole derivative that inhibits the interaction of ligands with rage |
| 05/25/2011 | EP2324812A2 Composition exhibiting enhanced formulation stability and delivery of topical active ingredients |
| 05/25/2011 | EP2323979A1 Treatment or prevention of hepatitis c with immunomodulator compounds |
| 05/25/2011 | EP2323692A1 Hangover relief by compositions comprising oral rehydration solution |
| 05/25/2011 | EP2323684A2 Use of a pneumococcal p4 peptide for enhancing opsonophagocytosis in response to a pathogen |
| 05/25/2011 | EP2323664A1 Use of a cdk inhibitor for the treatment of glioma |
| 05/25/2011 | EP2323656A1 Pharmaceutical product comprising a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist |
| 05/25/2011 | EP2323655A1 Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient |
| 05/25/2011 | EP2323485A1 Anti-allergen combinations of calcium and lanthanum salts |
| 05/25/2011 | EP1894576B1 Novel triglyceride reducing agent |
| 05/25/2011 | EP1534296B1 Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| 05/25/2011 | EP1439847B1 Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract |
| 05/25/2011 | EP1425035B1 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 05/25/2011 | EP1381384B1 COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha |
| 05/25/2011 | EP1374902B1 Anti-AILIM antibodies for the treatment of Crohn's disease |
| 05/25/2011 | EP1366077B1 PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST |
| 05/25/2011 | EP1335726B1 Modified prodrug forms of ap |
| 05/25/2011 | EP1263463B1 Use of an antibody or an immunotoxin that selectively binds to cd123 to impair hematologic cancer progenitor cells |
| 05/25/2011 | EP1183330B1 Kv10.1, A NOVEL VOLTAGE-GATED POTASSIUM CHANNEL FROM HUMAN BRAIN |
| 05/25/2011 | CN201840677U Preparation structure with carbon film layer |
| 05/25/2011 | CN1887296B Method of inducing antitumor immunity and its application in preparing medicine |
| 05/25/2011 | CN1871347B Method and kit for detecting proliferative diseases causing sclerosis, preventive and/or remedy for proliferative diseases causing sclerosis and method and kit for identifying substance efficacious in |
| 05/25/2011 | CN1845757B Use of cell factor mixture in preparing medicine for pre-sensitizing cancer and pharmaceutical composition for treating cancer |
| 05/25/2011 | CN102076337A Use of dronedarone for preparing a medicament for the treatment of patients with arrhythmia and having an increase of creatinine level due to dronedarone administration |
| 05/25/2011 | CN102068697A Opiates painkiller and opiate receptor antagonist-containing medicinal composition |
| 05/25/2011 | CN101502653B Medicament composition for preventing or treating Streptococcus suis disease |
| 05/25/2011 | CN101237870B Concomitant pharmaceutical agents and use thereof |
| 05/25/2011 | CN101227926B Use of composition in preparing medicine for treating osteoarthritis |
| 05/25/2011 | CN101185759B Anti-angiogene compositions and methods of use |
| 05/25/2011 | CN101085349B Vesicle guiding immunocyte and application of the same in preparing antineoplastic medicine |
| 05/25/2011 | CN101056628B Ester derivatives and medicinal use thereof |
| 05/24/2011 | US7947810 Kits for diagnosing a hypophosphatemic disorder |
| 05/24/2011 | US7947741 Use and administration of bacterial efflux pump inhibitors |
| 05/24/2011 | US7947684 anticoagulants; immunomoderators; antiinflammatory agents |
| 05/24/2011 | US7947648 Methods for treating asthma in human and non human primates using IL-4 mutant compositions |
| 05/24/2011 | US7947482 Strains of bifidobacterium having the ability to produce glutamine |
| 05/24/2011 | US7947462 Methods for identifying Kremen polypeptide binding partners |
| 05/24/2011 | US7947458 Placental human neurokinin B precursor |
| 05/24/2011 | US7947309 Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants |
| 05/24/2011 | US7947303 Supplement to be enterally administered for parenteral nutrition or partial enteral/oral nutrition of the critically ill, the chronically ill and people with malnutrition |
| 05/24/2011 | US7947299 Compositions and techniques for localized therapy |
| 05/24/2011 | US7947282 Methods of treatment using vascular occlusion in combination therapies |
| 05/24/2011 | US7947272 Using mixture comprising inhibitors of CD4, CD25 and interleukin induction as tool in reducing immune response to tissue graft; preventing transplant rejection |
| 05/24/2011 | US7947261 Moiety is positioned between a water-soluble polymer and a reactive group; water soluble polymer such as polyethylene glycol containing a urethane linkage moiety for example, and a reactive group for conjugating with biodrugs |
| 05/24/2011 | CA2582767C Solid formulation with improved solubility and stability and method for producing said formulation |
| 05/24/2011 | CA2509023C Multilayer dosage forms containing nsaids and triptans |
| 05/24/2011 | CA2506159C Fat regulation |
| 05/24/2011 | CA2504663C Methods of using and compositions comprising immunomudulatory compounds for the treatment and management of myeloproliferative diseases |
| 05/24/2011 | CA2493764C Improved treatment of cancer with glutamine |
| 05/24/2011 | CA2483012C Oligonucleotide compositions and their use for the modulation of immune responses |
| 05/24/2011 | CA2479737C Nanoparticulate compositions of map kinase inhibitors |
| 05/24/2011 | CA2471642C 6-fluorobicyclo[3.1.0]hexane derivatives |
| 05/24/2011 | CA2468719C Prevention and treatment of androgen-deprivation induced osteoporosis |
| 05/24/2011 | CA2463626C Piperidine- and piperazineacetamines as 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 05/24/2011 | CA2452412C Biodegradable injectable implants and related methods of manufacture and use |
| 05/24/2011 | CA2452408C Method and apparatus for the photomodulation of living cells |
| 05/24/2011 | CA2450467C Methods for modulating bladder function |
| 05/24/2011 | CA2441235C Aryl and biaryl compounds having mch modulatory activity |
| 05/24/2011 | CA2421562C A method of producing analgesia using sodium channel blocking compounds such as tetrodotoxin, saxitoxin and derivatives thereof |
| 05/24/2011 | CA2420621C Microparticle compositions and methods for the manufacture thereof |
| 05/24/2011 | CA2415403C Method for obtaining aqueous formulations of oxidation-sensitive active principles |
| 05/24/2011 | CA2412947C Method for treating a movement disorder |
| 05/24/2011 | CA2401604C Method of treating cancer with anti-neurotrophin agents |
| 05/24/2011 | CA2385266C Novel cell cycle checkpoint genes and proteins encoded thereby |
| 05/24/2011 | CA2382840C Improved topical compositions containing probiotic bacteria, spores, and extracellular products and uses thereof |
| 05/24/2011 | CA2374215C New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
| 05/24/2011 | CA2366050C Agents for intravitreal administration to treat or prevent disorders of the eye |
| 05/24/2011 | CA2358459C Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions |
| 05/24/2011 | CA2341642C Page-4, an x-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor |
| 05/24/2011 | CA2323072C Gfr.alpha.3 and its uses |